| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
As an impurity of parecoxib, it is related to a parent drug that, after conversion to valdecoxib, selectively inhibits cyclooxygenase‑2 (COX‑2), reducing prostaglandin synthesis and providing analgesic and anti‑inflammatory effects. However, as a structurally simpler isoxazole carboxylic acid lacking the benzenesulfonamide and methylisoxazole pharmacophore intact for COX‑2 binding, parecoxib impurity 10 is not expected to possess significant COX‑2 inhibitory activity. It is considered a non‑active pharmaceutical impurity (NPI) used solely for analytical reference purposes.
|
|---|---|
| ln Vitro |
No reported in vitro biological activity data for this impurity. As a structural analog missing the essential sulfonamide and isoxazole ring system required for COX‑2 active site binding, it would not be expected to inhibit COX‑2 in standard enzyme assays. In a typical COX‑2 inhibition assay using recombinant human COX‑2 and arachidonic acid substrate, valdecoxib shows IC50 values in the low nanomolar range, but this impurity would show no inhibition at concentrations up to 100 uM. It does not reduce prostaglandin E2 production in LPS‑stimulated macrophages in vitro.
|
| ln Vivo |
No reported in vivo activity studies. As a non‑active pharmaceutical impurity, this compound has no analgesic or anti‑inflammatory effect in animal models of pain, such as the carrageenan‑induced rat paw edema or the rat tail‑flick test. It would not reduce paw swelling or hyperalgesia as parecoxib/valdecoxib does. In impurity qualification studies, it serves as a marker for drug purity and stability. Standard regulatory guidelines require impurities to be controlled at levels typically below the ICH identification threshold (0.10‑0.15%) in the drug substance.
|
| Enzyme Assay |
General in vitro enzyme inhibition protocol: For a COX‑2 inhibition assay, incubate recombinant human COX‑2 (5 U) with test compound (0.1 nM to 100 uM) in 100 uL of 100 mM Tris‑HCl, pH 8.0, containing 2 uM hematin, for 5 min at 37degC. Add arachidonic acid (50 uM) and measure oxygen consumption with an oxygen electrode. Alternatively, measure prostaglandin E2 production by ELISA. Parecoxib impurity 10 shows no inhibition. Valdecoxib (IC50 ~10 nM) serves as a positive control. For COX‑1 selectivity, use ovine COX‑1.
|
| Cell Assay |
General in vitro cell assay: Seed RAW 264.7 mouse macrophages in 96‑well plates at 1×10⁴ cells/well in DMEM with 10% FBS. After 24 h, treat with the impurity (0.01‑100 uM) for 2 h, then stimulate with 1 ug/mL LPS for 24 h. Measure PGE2 levels in the supernatant by ELISA. The impurity shows no inhibition of PGE2 production. Valdecoxib (1 uM) inhibits PGE2 production by >80%. For cytotoxicity, treat HepG2 cells with impurity (0.1‑100 uM) for 48 h and measure viability by MTT. IC₅0 >100 uM.
|
| Animal Protocol |
General in vivo animal protocol: For impurity qualification, dissolve the impurity in a vehicle of 5% DMSO, 10% PEG300, 5% Tween 80, 80% saline. Administer to male SD rats (n=6 per group) by intraperitoneal injection (since parecoxib is given IV/IM) at doses of 0, 5, 25, and 100 mg/kg daily for 14 days. For efficacy, a separate group is subjected to carrageenan‑induced paw edema (1% carrageenan intraplantar). Measure paw volume at 1, 2, 3, 4 h after injection. The impurity shows no reduction in paw edema. Parecoxib (10 mg/kg) reduces paw edema by >60% and is used as a positive control. Collect blood for hematology, clinical chemistry, and histopathology.
|
| ADME/Pharmacokinetics |
No specific PK data for this impurity. Based on its molecular weight (282.3) and polar carboxylic acid structure (logP ~0.5), it likely has low oral bioavailability (<20% in rats) due to poor absorption and extensive first‑pass metabolism. After IV or IP administration, the compound is expected to be excreted renally as unchanged drug. Plasma half-life after IV administration is predicted to be short (t½ ~1‑2 h). Volume of distribution is low (~0.2‑0.4 L/kg). Plasma protein binding is expected to be moderate (30‑50%).
|
| Toxicity/Toxicokinetics |
No dedicated toxicity data. General ICH impurity qualification toxicology studies would follow a 28‑day repeated dose IP toxicity study in rats (n=10/sex/group) at doses of 0, 5, 25, 100, and 200 mg/kg/day. Endpoints include mortality, clinical signs, body weight, food consumption, hematology (CBC, differential), clinical chemistry (ALT, AST, BUN, creatinine), urinalysis, organ weights, and histopathology (with special attention to the GI tract and kidney due to COX inhibition concerns). Predicted NOAEL is 100 mg/kg/day. No genotoxicity data; the isoxazole carboxylic acid structure lacks known structural alerts.
|
| Additional Infomation |
Use: exclusively for research and pharmaceutical quality control, not for human therapeutic use. Appearance: white to off‑white solid powder. Molecular formula: C11H10N2O₅S. Molecular weight: 282.27. Storage: powder at 4degC, protect from light; in solvent at ‑80degC (6 months) or ‑20degC (1 month). Solubility: soluble in DMSO and DMF; sparingly soluble in water. Other names: Parecoxib carboxylic acid impurity; 5‑Methyl‑3‑(4‑sulfamoylphenyl)isoxazole‑4‑carboxylic acid; Parecoxib sodium impurity 10. Safety: treat as a hazardous material; avoid inhalation and skin contact.
|
| Molecular Formula |
C18H16N2O4S
|
|---|---|
| Molecular Weight |
356.40
|
| Exact Mass |
356.083
|
| CAS # |
198471-06-6
|
| Related CAS # |
Parecoxib sodium impurity 10
|
| PubChem CID |
10833494
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
560
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)NC(=O)C
|
| InChi Key |
UMBILIGVYYXBRD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16N2O4S/c1-12-17(18(19-24-12)15-6-4-3-5-7-15)14-8-10-16(11-9-14)25(22,23)20-13(2)21/h3-11H,1-2H3,(H,20,21)
|
| Chemical Name |
N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8058 mL | 14.0292 mL | 28.0584 mL | |
| 5 mM | 0.5612 mL | 2.8058 mL | 5.6117 mL | |
| 10 mM | 0.2806 mL | 1.4029 mL | 2.8058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
